Cases & Investigations
Berger Montague has filed a class action lawsuit against Volkswagen Group on behalf of consumers who drive a 2018 or 2019 Volkswagen Jetta. The new 8-speed transmission used in these Jetta models is grinding and often leaking oil.
Berger Montague, as a member of the plaintiffs’ steering committee, obtained settlements of $141 million for investors Walco. Plaintiffs invested in funding entities that were formed “exclusively” for the purpose of investing in an organization perpetrating the Ponzi scheme.
In 1999, Berger Montague, as co-lead counsel, obtained a class settlement for investors of $220 million cash which included a settlement against Waste Management’s outside accountants.
Berger Montague is investigating Wells Fargo for a potential class action lawsuit on behalf of current and former employees who claim they were not paid overtime compensation or not paid for all hours worked. Since September 2016, Wells Fargo has been the target of government investigations into an alleged fraudulent scheme to open millions of unauthorized checking and credit accounts on behalf of existing customers in order to enhance its sales figures.
Berger Montague settled this individual claim for a confidential amount, seeking interpretation of the distribution agreement for the movie Gone with the Wind and undistributed profits for the years 1993-1997, with forward changes in accounting and distribution.
Berger Montague is representing proposed classes of California and New York employers who participated in Applied Underwriters Inc.’s EquityComp or SolutionOne workers compensation insurance at any time between January 1, 2006 and the present.
Berger Montague, as co-lead counsel in the securities actions, obtained a cash settlement of $80 million on behalf of investors against Xcel Energy and certain of its officers and directors.
Berger Montague represents a proposed class of direct purchasers of the drug Zetia (ezetimibe). Plaintiffs allege that Merck & Co. Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., MSP Singapore Co. LLC (collectively, “Merck”), Glenmark Pharmaceuticals LTD, and Glenmark Generics Inc. (together, “Glenmark”) entered into a reverse payment agreement that delayed generic competition to Merck’s brand cholesterol drug Zetia.